Sources: Isomorphic Labs, an AI drug discovery startup spun out of Google DeepMind, is in early talks to raise funds at a valuation of at least $40B (Bloomberg)

Isomorphic Labs’ reported early funding talks at a $40B valuation underscore how quickly AI-native businesses are being priced on the promise of transforming high-value, research-intensive industries like pharmaceuticals. For CIOs and technology leaders, the signal is broader than biotech: AI is becoming a strategic lever for accelerating discovery, improving decision quality, and reshaping how organizations invest in data, compute, and model capabilities. IT organizations should view this as a reminder that competitive advantage will increasingly depend on building secure, governed AI platforms that can support mission-critical workflows in regulated environments.